Biotech company Sonoma Biotherapeutics has raised $265 million in new funding, the company announced Wednesday. The funding will be used to advance its programs aiming to treat autoimmune and inflammatory conditions such as rheumatoid arthritis and type 1 diabetes.
"The idea is that we are taking cells out of the body of patients, and we’re manipulating them and putting them back into the patients,” said CEO and president Jeff Bluestone, in a video, “So the cells become a therapy, they become the medicine.”